vs
Side-by-side financial comparison of Amarin Corp plc (AMRN) and Primis Financial Corp. (FRST). Click either name above to swap in a different company.
Primis Financial Corp. is the larger business by last-quarter revenue ($45.6M vs $45.1M, roughly 1.0× Amarin Corp plc). Primis Financial Corp. runs the higher net margin — 16.0% vs -23.3%, a 39.3% gap on every dollar of revenue. Over the past eight quarters, Primis Financial Corp.'s revenue compounded faster (13.0% CAGR vs -18.3%).
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
Primis Financial Corp is a U.S.-based financial holding company operating full-service banking subsidiaries. It provides a comprehensive range of financial solutions including personal and commercial deposit products, diverse loan facilities, mortgage services, and wealth management support, primarily serving retail and corporate customers across the U.S. mid-Atlantic region.
AMRN vs FRST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $45.1M | $45.6M |
| Net Profit | $-10.5M | $7.3M |
| Gross Margin | — | — |
| Operating Margin | 35.5% | — |
| Net Margin | -23.3% | 16.0% |
| Revenue YoY | 7.0% | — |
| Net Profit YoY | 33.0% | 200.0% |
| EPS (diluted) | — | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $45.1M | $45.6M | ||
| Q4 25 | $49.2M | $80.9M | ||
| Q3 25 | $49.7M | $41.0M | ||
| Q2 25 | $72.7M | $43.2M | ||
| Q1 25 | $42.0M | $58.7M | ||
| Q4 24 | $62.3M | $38.8M | ||
| Q3 24 | $42.3M | $37.3M | ||
| Q2 24 | $67.5M | $35.7M |
| Q1 26 | $-10.5M | $7.3M | ||
| Q4 25 | $-1.2M | $29.5M | ||
| Q3 25 | $-7.7M | $6.8M | ||
| Q2 25 | $-14.1M | $2.4M | ||
| Q1 25 | $-15.7M | $22.6M | ||
| Q4 24 | $-48.6M | $-26.2M | ||
| Q3 24 | $-25.1M | $1.2M | ||
| Q2 24 | $1.5M | $3.4M |
| Q1 26 | — | — | ||
| Q4 25 | 47.1% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 69.2% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | -15.4% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 63.4% | — |
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | 44.8% | ||
| Q3 25 | -22.4% | 21.3% | ||
| Q2 25 | -22.0% | 6.9% | ||
| Q1 25 | -39.9% | 41.9% | ||
| Q4 24 | -84.3% | -123.0% | ||
| Q3 24 | -59.5% | -3.1% | ||
| Q2 24 | -0.8% | 7.8% |
| Q1 26 | -23.3% | 16.0% | ||
| Q4 25 | -2.5% | 36.5% | ||
| Q3 25 | -15.6% | 16.7% | ||
| Q2 25 | -19.4% | 5.6% | ||
| Q1 25 | -37.4% | 38.6% | ||
| Q4 24 | -78.0% | -100.3% | ||
| Q3 24 | -59.4% | 3.3% | ||
| Q2 24 | 2.3% | 9.6% |
| Q1 26 | — | $0.30 | ||
| Q4 25 | $0.00 | $1.19 | ||
| Q3 25 | $-0.02 | $0.28 | ||
| Q2 25 | $-0.03 | $0.10 | ||
| Q1 25 | $-0.04 | $0.92 | ||
| Q4 24 | $-0.12 | $-0.95 | ||
| Q3 24 | $-0.06 | $0.05 | ||
| Q2 24 | $0.00 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $307.8M | $159.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $427.2M |
| Total Assets | $645.8M | $4.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $307.8M | $159.9M | ||
| Q4 25 | $302.6M | $143.6M | ||
| Q3 25 | $286.6M | $63.9M | ||
| Q2 25 | $298.7M | $94.1M | ||
| Q1 25 | $281.8M | $57.0M | ||
| Q4 24 | $294.2M | $64.5M | ||
| Q3 24 | $305.7M | $77.3M | ||
| Q2 24 | $306.7M | $66.6M |
| Q1 26 | — | $427.2M | ||
| Q4 25 | $459.3M | $422.9M | ||
| Q3 25 | $458.9M | $382.2M | ||
| Q2 25 | $464.9M | $376.4M | ||
| Q1 25 | $473.7M | $375.6M | ||
| Q4 24 | $486.2M | $351.8M | ||
| Q3 24 | $531.4M | $381.0M | ||
| Q2 24 | $551.9M | $376.0M |
| Q1 26 | $645.8M | $4.3B | ||
| Q4 25 | $670.8M | $4.0B | ||
| Q3 25 | $659.8M | $4.0B | ||
| Q2 25 | $670.1M | $3.9B | ||
| Q1 25 | $655.7M | $3.7B | ||
| Q4 24 | $685.3M | $3.7B | ||
| Q3 24 | $750.6M | $4.0B | ||
| Q2 24 | $799.9M | $4.0B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
FRST
| Net Interest Income | $32.1M | 70% |
| Noninterest Income | $13.6M | 30% |
